<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00482716</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000549549</org_study_id>
    <secondary_id>BARTS-06/Q0605/93</secondary_id>
    <secondary_id>ISRCTN11830961</secondary_id>
    <secondary_id>EU-20731</secondary_id>
    <nct_id>NCT00482716</nct_id>
  </id_info>
  <brief_title>Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer</brief_title>
  <official_title>Randomized Controlled Study of Iron Supplementation to Support the Response to Recombinant Human Erythropoietin for the Treatment of Chemotherapy-Induced Anaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Bartholomew's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Epoetin alfa and epoetin beta may cause the body to make more red blood cells. Red
      blood cells contain iron that is needed to carry oxygen to the tissues. It is not yet known
      whether epoetin alfa or epoetin beta are more effective when given with or without iron
      infusion in treating anemia in patients with cancer.

      PURPOSE: This randomized phase III trial is studying epoetin alfa or epoetin beta to compare
      how well they work with or without iron infusion in treating anemia in patients with cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the efficacy of recombinant epoetin alfa or epoetin beta with vs without
           parenteral iron in anemic, iron-replete patients with nonmyeloid malignancies.

      OUTLINE: This is a randomized, controlled, open-label, prospective study. Patients are
      randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive recombinant erythropoietic stimulatory activity (ESA) therapy
           comprising epoetin alfa or epoetin beta subcutaneously (SC) on day 1.

        -  Arm II: Patients receive ESA therapy as in arm I and parenteral iron (i.e., low
           molecular weight iron dextran complex IV over 5-10 minutes or iron sucrose injection IV
           over 10-30 minutes) on day 1.

      In both arms, treatment repeats weekly for up to 10 weeks or until hemoglobin reaches 13
      g/dL, whichever comes first.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum hemoglobin achieved</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to zenith hemoglobin or achievement of hemoglobin level ≥ 13 g/dL</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Anemia</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>epoetin alfa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>epoetin beta</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>iron dextran complex</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>iron sucrose injection</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of nonmyeloid malignancy

               -  No primary bone marrow malignancies except multiple myeloma, chronic lymphocytic
                  leukemia, or indolent non-Hodgkin lymphoma

          -  Candidate for erythropoietin stimulatory activity therapy for anemia due to cancer
             and/or chemotherapy

               -  Baseline hemoglobin ≤ 10.5 g/dL

               -  Planning to receive ≥ 6 additional weeks of chemotherapy for the malignancy

          -  Demonstrates iron-replete status as defined by all of the following parameters:

               -  Percent saturation of transferrin ≥ 20%

               -  Serum ferritin 225-2,250 pmol/L

               -  Reticulocyte hemoglobin content &gt; 31 pg

               -  Zinc protoporphyrin &lt; 80 µg/dL

          -  No anemia of origin other than cancer or cancer chemotherapy

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  No allergy or intolerance to recombinant epoetin alfa or epoetin beta

          -  No known sensitivity to iron sucrose injection or iron dextran complex

          -  No uncontrolled hypertension

          -  No active infection

          -  No active bleeding

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior iron sucrose injection or iron dextran complex therapy

          -  More than 6 months since prior and no concurrent transfusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samir G Agrawal, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>St. Bartholomew's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2007</study_first_submitted>
  <study_first_submitted_qc>June 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2007</study_first_posted>
  <last_update_submitted>January 9, 2014</last_update_submitted>
  <last_update_submitted_qc>January 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2014</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>contiguous stage II marginal zone lymphoma</keyword>
  <keyword>contiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>stage I adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage I grade 1 follicular lymphoma</keyword>
  <keyword>stage I grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage I marginal zone lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>stage I small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage I chronic lymphocytic leukemia</keyword>
  <keyword>stage II chronic lymphocytic leukemia</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Ferric oxide, saccharated</mesh_term>
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Iron-Dextran Complex</mesh_term>
    <mesh_term>Dextrans</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

